However, these results do suggest for the first time a therapeutically addressable target for reducing heightened disease activity in Asian SLE patients, suggesting that clinical trials of anti-MIF therapies in SLE39 could be considered particularly appropriate in this subgroup. Here, MIF is linked to systemic lupus erythematosus.